AR
AKYA

Advisory Research’s Akoya BioSciences AKYA Stock Holding History

Advisory Research’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-52,189
Closed -$499K – 354
2022
Q4 		$499K Sell
52,189
-31,924
-38% -$393K 0.05% 247
2022
Q3 		$989K Buy
+84,113
New +$1.11M 0.1% 166

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Advisory Research's AKYA Position: Q1 2023 in Review

Advisory Research sold out of Akoya BioSciences (AKYA) in Q1 2023, closing a stake of 52,189 shares — an estimated $499K sold.

Advisory Research first reported a position in AKYA in Q3 2022 and held it in 2 quarters. The position peaked at $989K in Q3 2022. 63 funds tracked by Wall St. Rank hold AKYA as of Q1 2023.

  • Advisory Research reported no remaining Akoya BioSciences position as of Q1 2023 after selling out during the quarter.
  • Advisory Research sold 52,189 Akoya BioSciences shares in Q1 2023, an estimated $499K.
  • Advisory Research first reported a position in Akoya BioSciences in Q3 2022 and held it in 2 quarters.
  • Advisory Research's Akoya BioSciences position peaked at $989K in Q3 2022.
  • 63 funds tracked by Wall St. Rank held Akoya BioSciences as of Q1 2023.

Based on Advisory Research's 13F filing for Q1 2023, filed 12 May 2023.